Copyright: ©Author(s) 2026.
World J Gastroenterol. Apr 14, 2026; 32(14): 115790
Published online Apr 14, 2026. doi: 10.3748/wjg.v32.i14.115790
Published online Apr 14, 2026. doi: 10.3748/wjg.v32.i14.115790
Table 4 Effect of protective agent uses on significant hemoglobin drop incidences for aspirin or clopidogrel alone users in self-controlled case series analyses
| Exposure period | Aspirin-alone users | Clopidogrel-alone users | Concurrent users of aspirin & clopidogrel (n = 30) | Concomitant users of aspirin & clopidogrel (n = 348) | ||||
| IRR (95%CI) | P value | IRR (95%CI) | P value | IRR (95%CI) | P value | IRR (95%CI) | P value | |
| All SHD events | ||||||||
| Mucosal DA alone | Reference | Reference | ||||||
| PPI | 0.33 (0.21-0.52) | < 0.001 | 0.43 (0.09-2.13) | 0.301 | 0.39 (0.10-1.60) | 0.191 | 0.43 (0.30-0.62) | < 0.001 |
| PPI & rebamipide | 0.35 (0.06-1.90) | 0.223 | ||||||
| PPI & H2RA | 0.54 (0.18-1.64) | 0.281 | ||||||
| PPI & others | 0.14 (0.02-1.02) | 0.052 | ||||||
| Rebamipide | 0.69 (0.36-1.34) | 0.276 | 0.25 (0.02-2.87) | 0.263 | 1.49 (0.87-2.57) | 0.148 | ||
| Rebamipide & H2RA | 0.61 (0.12-3.17) | 0.553 | 0.27 (0.05-1.35) | 0.111 | ||||
| H2RA | 0.60 (0.43-0.83) | 0.002 | 1.85 (0.55-6.23) | 0.322 | 1.02 (0.42-2.53) | 0.958 | 0.93 (0.67-1.29) | 0.661 |
| H2RA & others | 0.46 (0.07-2.95) | 0.411 | ||||||
| Others | 0.47 (0.20-1.10) | 0.081 | 2.34 (0.32-17.19) | 0.403 | 0.40 (0.15-1.07) | 0.068 | ||
| First SHD event only | ||||||||
| Mucosal DA alone | Reference | Reference | ||||||
| PPI | 0.33 (0.21-0.51) | < 0.001 | 0.42 (0.08-2.08) | 0.286 | 0.39 (0.10-1.60) | 0.191 | 0.45 (0.31-0.65) | < 0.001 |
| PPI & rebamipide | 0.35 (0.06-1.91) | 0.224 | ||||||
| PPI & H2RA | 0.81 (0.26-2.50) | 0.708 | ||||||
| PPI & others | 0.15 (0.02-1.04) | 0.055 | ||||||
| Rebamipide | 0.74 (0.38-1.44) | 0.380 | 0.26 (0.02-3.07) | 0.285 | 1.46 (0.85-2.52) | 0.173 | ||
| Rebamipide & H2RA | 0.60 (0.12-3.15) | 0.549 | ||||||
| H2RA | 0.62 (0.44-0.86) | < 0.001 | 2.22 (0.59-8.33) | 0.239 | 1.02 (0.42-2.53) | 0.958 | 0.96 (0.69-1.34) | 0.814 |
| H2RA & others | 0.45 (0.07-2.89) | 0.401 | ||||||
| Others | 0.48 (0.20-1.12) | 0.090 | 2.30 (0.31-16.93) | 0.413 | ||||
- Citation: Kim M, Chi SA, Kim JE, Kim ER, Hong SN, Kim YH, Kim K, Chang DK. Optimal strategies for mitigating gastrointestinal bleeding in patients receiving antiplatelet therapy: Real-world study. World J Gastroenterol 2026; 32(14): 115790
- URL: https://www.wjgnet.com/1007-9327/full/v32/i14/115790.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i14.115790